drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Autologous patient-derived CD4+/CD8+ T cells (LMY-920) gene-modified via a non-viral transposon to express a BAFF-ligand chimeric antigen receptor targeting BAFF-R/BR3, TACI, and BCMA to eliminate malignant B cells; dosed at 1–8×10^6 CAR+ cells/kg following lymphodepletion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous CD4+/CD8+ T cells engineered via a non-viral transposon to express a BAFF-ligand chimeric antigen receptor that binds BAFF family receptors (BAFF-R/BR3, TACI, BCMA) on malignant B cells; antigen engagement activates the CAR T cells to proliferate, secrete cytotoxic mediators/cytokines, and kill the target B cells.
drug_name
BAFF CAR-T
nct_id_drug_ref
NCT05312801